株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

カンジダ症:世界の治験動向

Candidiasis Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 244956
出版日 ページ情報 英文 214 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
カンジダ症:世界の治験動向 Candidiasis Global Clinical Trials Review, H1, 2017
出版日: 2017年05月31日 ページ情報: 英文 214 Pages
概要

当レポートでは、カンジダ症の治験 (臨床試験) に関する最新動向について分析しており、地域別の治験件数、治験の段階別進行状況、被験者採用の状況、有望なスポンサー、各企業や研究機関における研究の進行状況、有望な薬剤の比較といった情報をまとめています。

イントロダクション

  • カンジダ症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:感染症治療薬の治験におけるカンジダ症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:感染症治療薬の治験におけるカンジダ症の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

カンジダ症治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • Pfizer Inc.
    • アステラス製薬
    • Merck & Co., Inc.
    • Basilea Pharmaceutica AG
    • Johnson & Johnson
    • Bayer AG
    • Laboratory Corporation of America Holdings
    • GlaxoSmithKline Plc
    • Durata Therapeutics, Inc.
    • Bristol-Myers Squibb Company
  • 代表的な研究機関・病院の治験の概要
    • The National Institute of Allergy and Infectious Diseases
    • National Cancer Institute
    • Duke University
    • University Medical Center Groningen
    • Ahvaz Jundishapur University of Medical Sciences
    • Indian Council of Medical Research
    • Shahid Beheshti University
    • Shiraz University of Medical Sciences
    • Tehran University of Medical Sciences
    • The University of Melbourne

5つの代表的な治験のプロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC4239CTIDB

GlobalData's clinical trial report, "Candidiasis Global Clinical Trials Review, H1, 2017" provides an overview of Candidiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Candidiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Candidiasis to Infectious Disease Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Candidiasis to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Candidiasis Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Candidiasis 31
  • May 30, 2017: Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association 31
  • May 24, 2017: Eight SCY-078 Data Presentations at ASM Microbe 2017 Confirm Potential of SCYNEXIS' Lead Agent to Combat Serious and Life-threatening Fungal Infections 31
  • May 11, 2017: Potent in vitro Activity of SCYNEXIS SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida auris Further Confirmed in an in vitro Study Conducted by the Centers for Disease Control and Prevention 32
  • May 08, 2017: SCYNEXIS Provides Update on IV Formulation Development Status 33
  • Apr 25, 2017: Eight Data Presentations at ECCMID Showcase the Broad Applicability of SCYNEXIS' Lead Anti-infective Candidate SCY-078 33
  • Apr 17, 2017: Cidara Therapeutics to Present Data on Novel Antifungal CD101 at ECCMID and SID Annual Meetings 34
  • Clinical Trial Profile Snapshots 35

Appendix 212

  • Abbreviations 212
  • Definitions 212
  • Research Methodology 213
  • Secondary Research 213
  • About GlobalData 214
  • Contact Us 214
  • Source 214

List of Tables

List of Tables

  • Candidiasis Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Candidiasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Candidiasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Candidiasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Candidiasis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Candidiasis Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Candidiasis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Candidiasis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Candidiasis to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Candidiasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Candidiasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Candidiasis to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Candidiasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Candidiasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Candidiasis Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Candidiasis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Candidiasis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Candidiasis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Candidiasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Candidiasis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Candidiasis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Candidiasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Candidiasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Candidiasis Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Candidiasis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Candidiasis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Candidiasis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Candidiasis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Candidiasis Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Candidiasis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Candidiasis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Candidiasis to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Candidiasis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Candidiasis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Candidiasis to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Candidiasis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Candidiasis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Candidiasis Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Candidiasis Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Candidiasis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Candidiasis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Candidiasis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Candidiasis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Candidiasis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Candidiasis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Candidiasis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 213
Back to Top